



Gestational Trophoblastic Neoplasia Histopathology Reporting Guide

Family/Last name Date of birth Given name(s) Patient identifiers Date of request Accession/Laboratory number Elements in **black text** are CORE. Elements in **grey text** are NON-CORE. indicates multi-select values indicates single select values

SCOPE OF THIS DATASET

CLINICAL INFORMATION

 Information not provided**Age** (years) <40 ≥40**Antecedent/causative gestation**

(which may not be the immediate antecedent gestation)

 Information not provided Term pregnancy Missed abortion/spontaneous abortion Ectopic (tubal or ovarian) pregnancy Hydatidiform mole (complete or partial)**Interval times from the antecedent/causative gestation**

(months)

 Information not provided <4 4-6 7-12 >12**Presurgical serum hCG level** (mIU/ml) Information not provided <1,000 1,000-10,000 >10,000-100,000 >100,000**Previous failed chemotherapy** Information not provided None 1 drug ≥2 drugs

OPERATIVE PROCEDURE (select all that apply)

 Not specified Hysterectomy Simple total Simple supracervical/subtotal Radical Type not specified Pelvic exenteration Salpingectomy or salpingo-oophorectomy, *specify* Lymph nodes, *specify site(s)* Other, *specify*

SPECIMEN INTEGRITY

 Intact Opened Morcellated/fragmented Other, *specify*

TUMOUR SITE^{a,b} (select all that apply)

 Indeterminate Uterine corpus Uterine cervix Fallopian tube Left Right Not specified Ovary Left Right Not specified Broad ligament Vagina Other, *specify*^a Involving female genital organs.^b Where multiple sites are involved, report the primary tumour site.

TUMOUR DIMENSIONS

 <30 mm 30-50 mm >50 mm Cannot be assessed, *specify*

BLOCK IDENTIFICATION KEY

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)

HISTOLOGICAL TUMOUR TYPE 

(Value list based on the World Health Organization Classification of Female Genital Tumours (2020))

- Invasive hydatidiform mole (complete or partial)
- Gestational choriocarcinoma
- Placental site trophoblastic tumour (PSTT)
- Epithelioid trophoblastic tumour (ETT)
- Mixed trophoblastic tumour, *specify the tumour components and percentage of each component*

Other, *specify*

MITOTIC COUNT 

(Only applicable for PSTT and ETT)

- <5 mitoses/10 HPF
- ≥5 mitoses/10 HPF

OTHER TISSUE/ORGAN INVOLVEMENT (select all that apply) 

- Not identified
- Lung
- Spleen
- Kidney
- Gastrointestinal tract
- Liver
- Central nervous system
- Other tissue/organs, *specify*

Indeterminate, *explain reasons*

SEROSAL EXTENSION^c 

- Cannot be assessed
- Not identified
- Identified

^c Core element for PSTT and ETT; non-core element for invasive mole and choriocarcinoma.

LYMPHOVASCULAR INVASION 

- Indeterminate
- Not identified
- Present

MARGIN STATUS^c 

- Cannot be assessed
- Not involved

Distance of tumour from closest margin mm

Specify closest margin, if possible

Involved

Specify margin, if possible

^c Core element for PSTT and ETT; non-core element for invasive mole and choriocarcinoma.

LYMPH NODE STATUS 

- Cannot be assessed
- No nodes submitted or found

Site 1

Number of nodes examined

Number of positive nodes

Site 2

Number of nodes examined

Number of positive nodes

COEXISTING NON-NEOPLASTIC TROPHOBLASTIC LESIONS 

- None identified
- Present (select all that apply)
 - Exaggerated implantation/placental site (EPS)
 - Placental site nodule (PSN)
 - Non molar placental tissue
 - Hydatidiform mole
 - Other, *specify*

ANCILLARY STUDIES 

- Not performed
 Performed (select all that apply)

Immunohistochemistry performed for diagnosis, specify test(s) and result(s)

Immunohistochemistry performed for therapeutics (e.g., PD L1), specify test(s) and result(s)


DNA genotyping performed for diagnosis, specify test(s) and result(s)

DNA genotyping performed for risk score assessment, specify test(s) and result(s)

Representative blocks for ancillary studies, specify those blocks best representing tumour and/or normal tissue for further study

--

PATHOLOGICALLY CONFIRMED DISTANT METASTASIS

- Not identified 
 Present, specify site(s)

PROVISIONAL PATHOLOGICAL STAGING **FIGO (2001 edition)^d**

- I Gestational trophoblastic tumours strictly confined to the uterine corpus
 II Gestational trophoblastic tumours extending to the adnexae or to the vagina, but limited to the genital structures
 III Gestational trophoblastic tumours extending to the lungs, with or without genital tract involvement
 IV All other metastatic sites

^d Reprinted from *Int J Gynecol Cancer*, Volume 11(1), Kohorn EI, The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment, pages 73-7, 2001, with permission from BMJ Publishing Group.

TNM Staging (UICC TNM 8th edition 2016)^e

TNM Descriptors (only if applicable) (select all that apply)

- m - multiple primary tumours
 r - recurrent
 y - post-therapy

Primary tumour (pT)

- TX Primary tumour cannot be assessed
 T0 No evidence of primary tumour
 T1 Tumour confined to uterus
 T2^f Tumour extends to other genital structures: vagina, ovary, broad ligament, fallopian tube by metastasis or direct extension

^e Reproduced with permission. Source: *UICC TNM Classification of Malignant Tumours, 8th Edition*, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 6th October 2020).

^f Genital metastasis (vagina, ovary, broad ligament, fallopian tube) is classified T2.